Skip to main content
SpringerLink
Log in

The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Objective

This meta-analysis assessed the efficacy and safety of 5 mg/day vortioxetine compared to placebo for adult major depressive disorder.

Methods

We performed a meta-analysis of the double-blind, randomized, controlled clinical trials involving 5 mg/day vortioxetine in adult patients with major depressive disorder published on PubMed, EBSCO, and PsycINFO, and the Clinical Trials databases were searched from 2000 through October 2013. The abstracts for the Annual Meetings of the American Psychiatric Association (APA) and previous reviews were searched to identify additional studies. Results were expressed with odds ratios (ORs) with their 95 % confidence interval (CI). The effect size (ES) for the four studies was derived by computing the standardized mean difference (SMD). The data were pooled with a random effects model.

Results

Five RCTs met the selection criteria. Results of the meta-analysis showed the following: (1) The treatment response of 5 mg/day vortioxetine group was greater than placebo group (OR = 1.84, 95 % CI = 1.16–2.93, Z = 2.59, P = 0.010), and there was a significant antidepressant effect of vortioxetine (ES = 2.98, P = 0.001). However, there was no significant difference in remission (OR = 1.47, 95 % CI = 0.95–2.30, Z = 1.71, P = 0.090). (2) The common adverse effects included nausea, dizziness, headache, dry mouth, and diarrhea. There was a significant difference for nausea between the two groups (OR = 3.01, 95 % CI = 2.22–4.09, Z = 7.08, P = 0.00001), but no significant differences were observed for the other four adverse effects.

Conclusions

For the treatment of major depressive disorder, our results show that a dose of 5 mg/day vortioxetine was more effective, but more easily induced nausea, compared to placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Alvarez E, Perez V, Dragheim M et al (2012) A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol 15(5):589–600

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Baldwin DS, Loft H, Dragheim M (2012) A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol 22(7):482–491

    Article  CAS  PubMed  Google Scholar 

  • Bang-Andersen B, Ruhland T, Jorgensen M, Smith G et al (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 54(9):3206–3221

    Article  CAS  PubMed  Google Scholar 

  • Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  CAS  PubMed  Google Scholar 

  • Bidzan L, Mahableshwarkar AR, Jacobsen P et al (2012) Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol 22(12):847–857

    Article  CAS  PubMed  Google Scholar 

  • Bijlsma EY, Chan JS, Olivier B, et al. (2013) Sexual side effects of serotonergic antidepressants: mediated by inhibition of serotonin on central dopamine release? Pharmacol Biochem Behav

  • Boulenger JP, Loft H, Florea I (2012) A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol 26(11):1408–1416

    Article  PubMed  Google Scholar 

  • Chen G, Lee R, Højer AM et al (2013) Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 33(10):727–736

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Di Florio A, Forty L, Gordon-Smith K et al (2013) Perinatal episodes across the mood disorder spectrum. JAMA Psychiatry 70(2):168–175

    Article  PubMed  Google Scholar 

  • Egger M, Davey Smith G, Schneider M et al (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Hatta S, Duni A, Ng CG et al (2013) Effects of selective serotonin reuptake inhibitors (SSRIs) therapy on the female sexual response cycle of women with major depression. Clin Ter 164(1):11–15

    CAS  PubMed  Google Scholar 

  • Henigsberg N, Mahableshwarkar AR, Jacobsen P et al (2012) A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry 73(7):953–959

    Article  CAS  PubMed  Google Scholar 

  • Herman JB, Brotman AW, Pollack MH et al (1990) Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 51(1):25–27

    CAS  PubMed  Google Scholar 

  • Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

    Article  PubMed Central  PubMed  Google Scholar 

  • Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12

    Article  CAS  PubMed  Google Scholar 

  • Jain R, Mahableshwarkar AR, Jacobsen PL et al (2013) A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol 16(2):313–321

    Article  CAS  PubMed  Google Scholar 

  • Katona C, Hansen T, Olsen CK (2012) A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27(4):215–223

    Article  PubMed  Google Scholar 

  • Mahableshwarkar AR, Jacobsen PL, Chen Y (2013) A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin 29(3):217–226

    Article  CAS  PubMed  Google Scholar 

  • Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389

    Article  CAS  PubMed  Google Scholar 

  • Mørk A, Pehrson A, Brennum LT et al (2012) Pharmacological effects of vortioxetine: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther 340(3):666–675

    Article  PubMed  Google Scholar 

  • Murray CJ, Lopez AD (1997) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349(9064):1498–1504

    Article  CAS  PubMed  Google Scholar 

  • Musher JS (1990) Anorgasmia with the use of fluoxetine. Am J Psychiatry 147(7):948

    CAS  PubMed  Google Scholar 

  • Penninx BW, Beekman AT, Honig A et al (2001) Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 58(3):221–227

    Article  CAS  PubMed  Google Scholar 

  • Robinson, Robert G, Spalletta et al (2010) Poststroke depression: a review. Can J Psychiatry 55(6):341–349

    PubMed Central  PubMed  Google Scholar 

  • Rothschild AJ, Mahableshwarkar AR, Jacobsen P et al (2012) Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol 22(12):858–866

    Article  CAS  PubMed  Google Scholar 

  • Schlienger JL (2013) Type 2 diabetes complications. Presse Med 42(5):839–848

    Article  PubMed  Google Scholar 

  • Ustün TB, Ayuso-Mateos JL, Chatterji S et al (2004) Global burden of depressive disorders in the year 2000. Br J Psychiatry 184:386–392

    Article  PubMed  Google Scholar 

  • World Health Organization.Mental Health.Depression.http://www.who.int/mental_health/management/depression/definition/en/Accessed 2-15-2012.

Download references

Acknowledgments

This systematic review was supported by the National Natural Science Foundation of China (No.81171225).

Author information

Authors and Affiliations

  1. Department of Neurology, The Second Hospital Affiliated of Chongqing Medical University, Yuzhong Region, Linjiang Road, Chongqing, 400010, China

    Jie Fu & Yangmei Chen

Authors
  1. Jie Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yangmei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yangmei Chen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, J., Chen, Y. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis. Psychopharmacology 232, 7–16 (2015). https://doi.org/10.1007/s00213-014-3633-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-014-3633-z

Keywords

Search

Navigation